James Larkin, MD, PhD gives an update on the clinical trial CheckMate 067, a phase 3 study of Nivolumab or Nivolumab plus Ipilimumab versus Ipilimumab alone in previously untreated advanced melanoma.
This updated was presented at the 2015 National Cancer Research Institute (NCRI) Cancer Conference.
